Cardiogenic shock. [Review]
Cardiogenic shock. [Review]
Available online from MWHC library: 1996 - present, Available in print through MWHC library: August 1998 - February 2004
Cardiogenic shock (CS) is a condition in which a marked reduction in cardiac output and inadequate end-organ perfusion results from an array of cardiac insults, the most common of which is acute myocardial infarction. CS is a systemic disease involving a vicious cycle of inflammation, ischemia, and progressive myocardial dysfunction, which often results in death. This life-threatening emergency requires intensive monitoring accompanied by aggressive hemodynamic support; other therapies are tailored to the specific pathophysiology. The development of novel therapeutic strategies is urgently required to reduce the unacceptably high mortality rates currently associated with CS. Copyright 2013 Elsevier Inc. All rights reserved.
English
0733-8651
*Shock, Cardiogenic/th [Therapy]
Assisted Circulation/mt [Methods]
Cardiovascular Agents/tu [Therapeutic Use]
Coronary Care Units
Extracorporeal Membrane Oxygenation
Heart Rupture, Post-Infarction/di [Diagnosis]
Heart Rupture, Post-Infarction/su [Surgery]
Heart-Assist Devices
Hemodynamics/ph [Physiology]
Humans
Myocardial Revascularization/mt [Methods]
Prognosis
Randomized Controlled Trials as Topic
Shock, Cardiogenic/di [Diagnosis]
Shock, Cardiogenic/et [Etiology]
Ventricular Dysfunction, Right/di [Diagnosis]
Ventricular Dysfunction, Right/th [Therapy]
MedStar Heart & Vascular Institute
Journal Article
Review
Available online from MWHC library: 1996 - present, Available in print through MWHC library: August 1998 - February 2004
Cardiogenic shock (CS) is a condition in which a marked reduction in cardiac output and inadequate end-organ perfusion results from an array of cardiac insults, the most common of which is acute myocardial infarction. CS is a systemic disease involving a vicious cycle of inflammation, ischemia, and progressive myocardial dysfunction, which often results in death. This life-threatening emergency requires intensive monitoring accompanied by aggressive hemodynamic support; other therapies are tailored to the specific pathophysiology. The development of novel therapeutic strategies is urgently required to reduce the unacceptably high mortality rates currently associated with CS. Copyright 2013 Elsevier Inc. All rights reserved.
English
0733-8651
*Shock, Cardiogenic/th [Therapy]
Assisted Circulation/mt [Methods]
Cardiovascular Agents/tu [Therapeutic Use]
Coronary Care Units
Extracorporeal Membrane Oxygenation
Heart Rupture, Post-Infarction/di [Diagnosis]
Heart Rupture, Post-Infarction/su [Surgery]
Heart-Assist Devices
Hemodynamics/ph [Physiology]
Humans
Myocardial Revascularization/mt [Methods]
Prognosis
Randomized Controlled Trials as Topic
Shock, Cardiogenic/di [Diagnosis]
Shock, Cardiogenic/et [Etiology]
Ventricular Dysfunction, Right/di [Diagnosis]
Ventricular Dysfunction, Right/th [Therapy]
MedStar Heart & Vascular Institute
Journal Article
Review